Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.56 |
| ▸ | KIF11 | P52732 | 4/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921455 | 1.00 | EPHX2 (0.56) | EPHX2KIF11CA1CA2DHODH | |
| SCHEMBL1921452 | 0.92 | KIF11 (0.68) | EPHX2KIF11CA1CA2 | |
| SCHEMBL16481461 | 0.90 | MAOB (0.49) | EPHX2KIF11CA1CA2DHODH | |
| SCHEMBL503225 | 0.90 | ALDH1A1 (0.62) | EPHX2KIF11KMT2AALDH1A1TSHR | |
| SCHEMBL23059923 | 0.88 | AKR1C3 (0.50) | EPHX2KIF11CA1CA2DHODH | |
| SCHEMBL2705763 | 0.88 | EPHX2 (0.47) | EPHX2KIF11CA1CA2DHODH | |
| SCHEMBL2131497 | 0.88 | KIF11 (0.64) | EPHX2KIF11CA1CA2DHODH | |
| SCHEMBL6421472 | 0.88 | KIF11 (0.58) | EPHX2KIF11DHODHKMT2A | |
| SCHEMBL1981416 | 0.88 | HPGD (0.54) | EPHX2KIF11CA1CA2DHODH | |
| SCHEMBL11219337 | 0.88 | KIF11 (0.64) | EPHX2KIF11CA1CA2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119798332-A | Synthesis method and application of quaternary ring near infrared iridium complex based on SS coordination | 云南大学 | 2025-04-11 | — | — | CN | claimed |
| US-11261403-B2 | Stabilized compositions comprising leuco compounds | MILLIKEN & COMPANY (US) | 2022-03-01 | — | — | US | claimed |
| US-11136535-B2 | Leuco colorants as bluing agents in laundry care compositions | THE PROCTER & GAMBLE COMPANY (US) | 2021-10-05 | — | — | US | claimed |
| EP-3830232-A1 | LEUCO COLORANTS AS BLUING AGENTS IN LAUNDRY CARE COMPOSITIONS | The Procter & Gamble Company (US) | 2021-06-09 | — | — | EP | claimed |
| CN-112513238-A | Stable compositions comprising leuco compounds | 美利肯公司 | 2021-03-16 | — | — | CN | claimed |
| US-20200032167-A1 | STABILIZED COMPOSITIONS COMPRISING LEUCO COMPOUNDS | MILLIKEN & COMPANY | 2020-01-30 | — | — | US | claimed |
| US-20200032173-A1 | LEUCO COLORANTS AS BLUING AGENTS IN LAUNDRY CARE COMPOSITIONS | THE PROCTER & GAMBLE COMPANY | 2020-01-30 | — | — | US | claimed |
| WO-2020023812-A1 | LEUCO COLORANTS AS BLUING AGENTS IN LAUNDRY CARE COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2020-01-30 | — | — | WO | claimed |
| US-12577373-B2 | Carbodiimide composition, curing agent composition, coating composition and resin cured product | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2026-03-17 | — | — | US | disclosed |
| EP-4692071-A1 | PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASS | TOKUYAMA CORPORATION (JP) | 2026-02-11 | — | — | EP | disclosed |
| CN-119798332-A | Synthesis method and application of quaternary ring near infrared iridium complex based on SS coordination | 云南大学 | 2025-04-11 | — | — | CN | disclosed |
| WO-2024202086-A1 | PHOTOCHROMIC COMPOUND, NAPHTHOL DERIVATIVE, CURABLE COMPOSITION, OPTICAL ARTICLE, LENS, AND EYEGLASS | 株式会社トクヤマ | 2024-10-03 | — | — | WO | disclosed |
| CN-117616032-A | Rare earth complex | 东曹株式会社 | 2024-02-27 | — | — | CN | disclosed |
| US-20230392018-A1 | COMPOSITIONS COMPRISING LEUCO COMPOUNDS AND COLORANTS | MILLIKEN & COMPANY | 2023-12-07 | — | — | US | disclosed |
| EP-1153938-A1 | CATALYST FOR STEREOREGULAR POLYMERIZATION OF ALPHA-OLEFIN AND PROCESS FOR PRODUCING STEREOREGULAR ALPHA-OLEFIN POLYMER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-11-14 | — | — | EP | disclosed |
| US-20010020075-A1 | Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-09-06 | — | — | US | disclosed |
| US-6284699-B1 | COORDINATION POLYMERIZATION CATALYSTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-09-04 | — | — | US | disclosed |
| EP-1114832-A1 | Modified particles, catalyst for olefin polymerization using the same, and process of producing olefin polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-07-11 | — | — | EP | disclosed |
| US-20010007007-A1 | Modified particles, catalyst for olefin polymerization using the same, and process of producing olefin polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-07-05 | — | — | US | disclosed |
| EP-1113026-A2 | Catalyst component for addition polymerization, catalyst for addition polymerization, and process for producing addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577373-B2 | Carbodiimide composition, curing agent composition, coating composition and resin cured product | CD38, PARP9, MCCC2 | EPHX2 1451/4885KIF11 3858/4885CA1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.